-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TUwTo08RPQ7woaxoXe4mKpoo9GJqOzP7YsRYas3fRKnFu3vH79wqHxKN9BQIAio6 TBQmg2sfQXQ+7tVkpcMQJw== 0001036050-99-002363.txt : 19991115 0001036050-99-002363.hdr.sgml : 19991115 ACCESSION NUMBER: 0001036050-99-002363 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19991111 FILED AS OF DATE: 19991112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PHOENIX INTERNATIONAL LIFE SCIENCES INC CENTRAL INDEX KEY: 0000935016 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 223209631 FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 6-K SEC ACT: SEC FILE NUMBER: 000-29942 FILM NUMBER: 99749631 BUSINESS ADDRESS: STREET 1: 2350 COHEN STREET STREET 2: ST LAURENT QUEBEC CITY: H4R 2P7 CANADA STATE: A8 ZIP: 00000 6-K 1 PHOENIX INTERNATIONAL LIFE SCIENCES, INC FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Dated November 12, 1999 PHOENIX INTERNATIONAL LIFE SCIENCES INC. ---------------------------------------- (Translation of registrant's name into English) 2350 Cohen Street ----------------- Saint Laurent, Quebec Canada H4R 2N6 ------------------------------------ (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F X (commenced in calendar ----- ----- year 1998) Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No X ----- ----- If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): ---------------------- SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PHOENIX INTERNATIONAL LIFE SCIENCES INC. ---------------------------------------- (Registrant) Date: November 12, 1999 By: /s/ David Moszkowski ------------------ ------------------------------------- David Moszkowski Senior Vice President and Chief Financial Officer EX-99.1 2 PRESS RELEASE DATED 11/04/99 EXHIBIT 99.1 ------------ FOR IMMEDIATE RELEASE PHOENIX INTERNATIONAL DIVESTS 20% OF PHARMACEUTICAL SOFTWARE DIVISION Spin-off to create independent pharmaceutical software solutions Company called INTEGRAWARE Montreal, Quebec - November 4, 1999 - Phoenix International Life Sciences Inc. (NASDAQ: PHXI; TSE/ME: PHX) today announced the divestment of 20% of its pharmaceutical software division to employees. The divestiture will result in the formation of a new company called INTEGRAWARE, majority owned by Phoenix. "This initiative reflects our increasing focus on our core clinical research business," said Ian Lennox, CEO of Phoenix International. "Phoenix will remain an important customer of INTEGRAWARE and will continue as a shareholder in the company." INTEGRAWARE develops and markets innovative e-R&D software solutions for global pharmaceutical drug development. The company's protocol-driven and study-based systems are designed to integrate and accelerate bioanalysis, pharmacokinetics, metabolism, chromatography and other clinical activities. INTEGRAWARE also provides extensive services including, implementation, validation, training and software customization. In addition, INTEGRAWARE provides support for protocol design as well as sample and laboratory management. Its e-R&D automated solutions enhance formulation preparation, simplify drug administration, and facilitate sample collection to optimise data integrity and accelerate drug development. Jim Conklin, President and CEO of INTEGRAWARE, stated, "INTEGRAWARE will provide state-of-the-art service and solutions to a wide range of customers in the pharmaceutical, biotechnology, and contract research (CRO) industries. As part of Phoenix, we have developed extensive experience, industry expertise and a strong reputation for innovation. We look forward to building on our core competencies and establishing ourselves as a key player in the pharmaceutical software marketplace." Ian Lennox, CEO, Phoenix International, added: `Today, even though INTEGRAWARE leaves Phoenix and becomes a distinct business entity, we remain an important customer. INTEGRAWARE brings with it some of the top scientific minds in the business and will provide its customers with cutting-edge software solutions.' About Phoenix International Phoenix International is one of the world's leading contract research organizations. The Company provides a wide spectrum of clinical, analytical, preclinical, drug discovery support and ancillary services to the pharmaceutical and biotechnology industries. Since beginning its operations in 1989, Phoenix International has grown to approximately 2,400 employees worldwide, of whom more than 215 have either medical degrees or PhD's and over 240 others have masters level education. Headquartered in Montreal, Quebec, Phoenix International has operations throughout Europe and North America and research facilities in Australia, Israel and South Africa. Phoenix International is on the world wide web at www.pils.com. ------------ This release contains "forward-looking" statements regarding future results and events, including statements regarding expected future revenues, earnings and growth rates and goals and operating plans of management. Phoenix's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Factors that may cause such a difference include, but are not limited to: the inability of Phoenix to win new business at the levels required; the cancellation or delay of contracts; risks associated with the management of growth and the ability to attract and retain employees; risks of integrating newly acquired businesses; competition; any claims for patent infringement; unanticipated costs in connection with Year 2000 conversion; the ability to obtain future financing; adverse regulatory developments; foreign exchange rate fluctuations; and uncertainty surrounding the Euro. FOR MORE INFORMATION, PLEASE CONTACT: Michael S. Oleksiw Richard Gareau Director, Marketing Director, Communications Integraware Inc. Phoenix International Tel: (514) 335-8336 Tel.: (514) 333-0042 Fax: (514) 335-8338 Fax: (514) 333-7306 E-mail: michael.oleksiw@integraware.com E-mail: gareaur@pils.com ------------------------------- -----END PRIVACY-ENHANCED MESSAGE-----